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Dear Editor,
W e would like to share some clinical cases of late onset acute Vogt-Koyanagi-Harada syndrome (VKH), a rare 
diagnosis in this age range. 
This is an autoimmune inflammatory condition mediated by 
T cells that target melanocytes, manifests as a severe bilateral 
granulomatous panuveitis and is associated with systemic 
involvement, including central nervous system, audiovestibular 
and dermatological findings[1]. It usually affects women in 
their second to fourth decade of life, and is more common in 
Asia, Latin America and Middle East[1]. However, newer cases 
among elderly seem to be growing, as recently reported, with 
10% of a Japanese cohort of VKH patients being diagnosed 
after 65y[2]. Adding to this, there were other reports in the 
literature regarding older patients, with the oldest patient 
diagnosed at 89y, in Asia[3].
Clinical features, proposed treatment, side effects and 
management of three patients with late onset acute disease are 
described. The diagnosis was based on the Revised Diagnosis 
Criteria for VKH-2001[4]. 
Case 1  A 62y Caucasian man presented with painless, rapidly 
progressive visual loss in both eyes (OU) for 2wk, and ocular 
hyperemia, holocranial headache, tinnitus and hearing loss. No 
history of ocular trauma or surgery was reported.
Best corrected visual acuity (BCVA) was light perception 
(LP) OU. Slit-lamp examination (SLE) demonstrated: 
conjunctival hyperemia, cornea with Descemet’s folds, fine 
keratic precipitates (KP), shallow anterior chamber and 
Tyndall 3+ OU. Fundoscopy showed vitritis 1+, hyperemic 
edematous optic disc with total serous retinal detachment 
(RD) OU. Ocular ultrasonography showed total exudative RD 
and choroidal detachment 360° OU (Figure 1). Infectious and 
autoimmune causes were excluded.
Pulse therapy with methylprednisolone 1 g/d for 3d was 
initiated and hallucinations developed. Treatment then 
followed to oral prednisone 1 mg/kg·d with prednisolone 
acetate 1% and tropicamide 1% drops. Two weeks later, despite 
ocular and systemic improvement, BCVA was still LP OU. By 
this time, the patient experienced dizziness, weight gain and 
systemic arterial hypertension (SAH). Intravitreal injections of 
triamcinolone acetonide (IVT) OU was given along with oral 
cyclosporine 5 mg/kg·d, and slow tapering of oral steroids was 
initiated.
During follow-up, he developed 2 episodes of anterior segment 
recurrences and posterior subcapsular cataracts (PSC). 
Alopecia, poliosis and hair depigmentation were also observed. 
After 15mo follow-up, he was still on cyclosporine 5 mg/kg·d 
and prednisone 10 mg/d. BCVA improved to 20/70 in OD and 
20/40 in OS.
Case 2  A 62y Caucasian male presented with painless and 
sudden visual loss OU for 4d. BCVA in OD was 20/70 and 
20/200 in OS. There was no prior history of surgical or ocular 
trauma. 
He had granulomatous KPs and Tyndall 2+ OU on SLE and 
fundoscopy showed serous RD OU and hyperpigmentation 
areas in mid periphery of OD (Figure 2). Infectious and 
autoimmune testing was negative.
Oral prednisone 1.5 mg/kg·d and topical treatment OU were 
started and after 1mo, BCVA improved to 20/40 OU. However, 
cystoid macular edema OU was present and IVT OU was 
performed after which slow tapering of oral and topical 
steroids was attempted. Nevertheless, the patient had two 
recurrences manifesting as new RD OU, responsive to high 
dose oral and IVT. Cataracts OU developed and systemic side 
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effects included SAH, hyperglycemia and weight gain. Oral 
cyclosporine 5 mg/kg·d was introduced so oral steroids could 
be slowly tapered to 12.5 mg/d. Final BCVA was 20/40 OU.
Case 3  A 70y Caucasian woman with episodes of fever and 
malaise for 3mo, followed by visual loss 1mo before, came to 
our department. She was already on oral prednisone 40 mg/d. 
Past medical history included systemic arterial hypertension 
and ophthalmological background was unremarkable. 
At examination BCVA was hand movements in OD and LP 
in OS. Brownish KPs, posterior synechiae and PSC OU were 
present. Fundoscopy showed total serous RD with extensive 
areas of proliferative vitreoretinopathy (PVR) OU (Figure 3).
Systemic steroids dosing was maintained and additional 
local treatment was given: IVT in OD and dexamethasone 
intravitreal implant in OS. Despite initial improvement in OS, one 
month later BCVA dropped to LP OU associated with bilateral 
serous RD. Pulse therapy was initiated but SAH became 
uncontrolled and she needed to be admitted to the hospital. 
During the following 4mo, despite oral cyclosporine 
8 mg/kg·d,  azathioprine 3.5 mg/kg·d and steroids 
0.75 mg/kg·d, systemic symptoms disease-related totally 
improved, ophthalmological examination remained unchanged 
and SAH was still difficult to control. Phacoemulsification 
with intraocular lens implantation, posterior vitrectomy with 
membrane peeling, endolaser and silicone oil tamponade was 
performed OU. However, VA remained unchanged.
The authors believe these cases represent a good opportunity 
to emphasize the trend on the diagnosis of VKH in more 
advanced ages. These cases may not only have unusual 
demographical characteristics (since all patients were 
Caucasian Brazilian, two of whom were men) but also a 
more aggressive course and hard to control disease. Clinical 
evaluation, treatment and outcomes are summarized in Table 1. 
Older patients pose several challenges. The diagnosis may be 
delayed and difficult to establish, compromising outcomes: 
systemic and ocular comorbidities (cataract and macular 
Figure 2 Retinography before treatment  OD showing areas of retinal hyperpigmentation in the mid periphery and OS showing serous retinal 
detachment, respectively.
Figure 3 Retinography before surgery  Total serous detachment in OU with advanced PVR in OD and OS, respectively.
Figure 1 Ocular ultrasonography  Total serous retinal detachment. No retinal tears and 360° choroidal detachment OU.
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disease) may mimic VKH’s signs and elderly patients may 
find more difficult to access health care system[3]. Fortunately, 
the first two cases were diagnosed within a month after initial 
symptoms. However, that was not the case with patient 3, 
with longer time elapsed until diagnosis, which could have 
contributed to the outcome.
Once the diagnosis is established, clinical manifestations 
of VKH seem to be more aggressive in elderly. The largest 
cohort with patients older than 60y included 7 cases, in which 
cataract, optic disc hyperemia and choroidal detachment were 
more likely to occur, possibly correlating with more severe 
inflammation. Adding to this, elderly patients needed higher 
steroids dose than younger, supporting this hypothesis[2]. Our 
cases corroborate these and add further information: all patients 
presented severe anterior and posterior segment manifestations 
(such as hyperemic optic disc, serous RD with or without 
PVR, choroidal detachment), all had systemic involvement 
and all developed cataract (in which both inflammatory trigger 
and IVT injections might have contributed). Moreover, cases 
1 and 2 presented recurrences during steroid tapering and 
while on immunosuppressants, and case 3 did not improve, 
demonstrating the severity and persistency of inflammation. 
Treatment is the third challenge. The majority of these patients 
have comorbidities and adequate disease control without 
compromising general health is difficult[3]. Standard treatment 
includes early high dose systemic steroids (≥1 mg/kg), preferably 
within 2wk from the beginning of symptoms, followed by 
slow tapering. Treatment should be no less than 6mo and the 
dose should not be below 0.75 mg/kg·d until 4th month, titrated 
according to inflammation’s level[5-6]. All our patients had high 
dose steroid therapy although adequate time and dose was 
impossible due to side effects: overall our patients developed 
weight gain, hallucinations, dizziness, hyperglycemia and 
uncontrolled high blood pressure, forcing earlier tapering.
Local steroids and systemic immunosuppressive therapy 
(IMT), may be used in association with systemic steroids to 
reduce their dose or even precluding their use in selected cases, 
while promoting adequate control of inflammation. Almost 
78% of VKH patients treated with isolated posterior subtenon 
triamcinolone in acute onset VKH had complete resolution 
of ocular disease[7]. Fluocinolone acetonide implant may also 
reduce daily oral steroid dose and recurrence rates[8]. In our 
report, all eyes were treated with intravitreal steroids. Increase 
in local suppression of inflammation occurred in cases 1 and 2, 
but not in the long run in case 3, possibly due to its impressive 
severity. Regarding IMT, there is still no consensus regarding 
which agent is more advantageous and which patients would 
benefit the most. A significant reduction in recurrence rates, 
late complications and improvement in visual outcome in acute 
disease was reported with IMT combined with steroids as first-
line therapy[9]. However, Urzua et al[10] emphasized that earlier 
IMT in association with steroids was only superior in patients 
with initial visual acuity ≤20/200, fundus depigmentation, 
chronic disease and tinnitus. Regarding agent choice, there are 
Table 1 Demographics, clinical characteristics and outcomes
Clinical Presentation, 
Management and
Outcome
Case 1 Case 2 Case 3
Sex Male Male Female
Age (y) 62 62 70
Ethnicity Caucasian Caucasian Caucasian
Ocular
manifestations
Severe anterior segment signs: Tyndall 3+; severe 
posterior segment signs: hyperemic optic disc, 
choroidal detachment (besides serous RD)
Severe anterior segment signs: 
mutton-fat KP; Tyndall 2+; serous 
RD
Severe anterior segment signs: mutton-fat 
KP; posterior synechiae; serous RD with 
PVR
Systemic 
manifestations
Headache, tinnitus, hearing loss Painless and sudden visual loss Fever, malaise
Time elapsed until
treatment
2wk 4d Over 1mo
Systemic steroid
treatment
Pulse therapy; prednisone 1 mg/kg·d 1.5 mg/kg·d 0.75 mg/kg·d and pulse therapy
Local adjuvant
therapy
OD: IVT; OS: IVT None OD: IVT; OS: dexamethasone implant
IMT Cyclosporin 5 mg/kg·d Cyclosporin 5 mg/kg·d Cyclosporin 8 mg/kg·d; azathioprine
3.5 mg/kg·d
Side effects Hallucinations, dizziness, SAH, weight gain SAH, hyperglycemia, weight gain Uncontrolled SAH
Follow-up 2 episodes of anterior segment recurrences; 
alopecia, poliosis, vitiligo
2 episodes of posterior segment 
recurrences
No improvement
Initial BCVA OD: LP; OS: LP OD: 20/70; OS: 20/200 OD: HM; OS: LP
Final BCVA OD: 20/70; OS: 20/40 OD: 20/40; OS: 20/40 OD: HM; OS: LP
HM: Hand movements; IVT: Intravitreal triamcinolone; KP: Keratic precipitates; LP: Light perception; OD: Right eye; OS: Left eye; PVR: 
Proliferative vitreoretinopathy; RD: Retinal detachment; SAH: Systemic arterial hypertension.
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no randomized controlled clinical trials to support one specific 
agent. Cyclosporine performed better as a steroid-sparing 
agent in a study with chronic VKH patients[11] but methotrexate 
and mycophenolate mofetil achieved good results in another 
study involving acute and chronic VKH patients[12]. Our 
patients received early cyclosporine due to the severe initial 
presentation and although infections were a concern, no events 
were reported.
Although visual prognosis is good in the majority of cases, 
with 70%-80% with BCVA≥20/40[13], more than half may 
progress to chronic disease, due to delayed treatment and 
suboptimal dosing, or develop complications (cataract, 
glaucoma, choroidal neovascularization and subretinal 
fibrosis)[5,14]. Clinical presentation, such as poor VA (≤20/200), 
severe anterior segment inflammation (mutton-fat KPs, 
anterior chamber reaction ≥2+, iris nodules and posterior 
synechiae) and less exudative RD may be associated with 
chronic recurrent disease[13]. However, adequate steroid therapy 
remains the most important factor influencing outcome[14]. In 
our series, despite early treatment in cases 1 and 2, 5/6 eyes 
presented final VA≤20/40 and major contributors to these 
results were probably the severity of initial presentation and 
the need of early steroid tapering.
Some authors theorize that posterior recurrences and those 
occurring within six months are usually associated with failure 
regarding steroid treatment (late initiation, inadequate dose and 
quick or early withdrawal) leaving some specific T-cells against 
active melanocytes that cause subsequent recurrences[15]. This 
was the case with patients 1 and 2, emphasizing the difficulty 
in managing these patients and the concomitant higher level of 
inflammation[2].
In conclusion, although not common, VKH may occur in 
patients above 60y. In this setting, inflammation can be more 
severe and hard to control. High-dose steroid therapy should 
be started as soon as possible, but side effects may preclude 
it, especially in this subset of patients in which systemic 
comorbidities are common. Considering this, other therapeutic 
options, such as local steroids injections and IMT, should be 
considered early in the course of disease.
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